The US Government keeps an online database, at clinicaltrials.gov, of clinical research studies for Mesothelioma cancer, but doesn't review or approve the safety and science of these trials. The website is maintained by the National Library of Medicine (NLM). The links below go to the clinical trial information on clinicaltrials.gov. Talk with your health care professional about possible risks and benefits before joining any studies.
Thu, 10 Jul 2025 00:00:00 EDT
Conditions: Mesothelioma; Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Ovarian Neoplasms; Lung Neoplasms; Thymus Neoplasms; Colonic Neoplasms
Interventions: Device: mesothelin expression testing; Biological: TNhYP217 CAR T Cells; Drug: fludarabine; Drug: cyclophosphamide
Sponsors: National Cancer Institute (NCI)
Recruiting
Thu, 3 Jul 2025 00:00:00 EDT
Conditions: Pleural Mesothelioma; Pleural Diseases; Cancer; FAPI; Fibroblast Activation Protein Inhibitor
Interventions: Drug: [68Ga]Ga-FAPI-46 PET/CT
Sponsors: Aalborg University Hospital
Recruiting
Thu, 3 Jul 2025 00:00:00 EDT
Conditions: Mesothelin-Expressing Tumors; Epithelial Ovarian Cancer; Malignant Pleural Mesothelioma, Advanced; Malignant Peritoneal Mesothelioma, Advanced; Pancreatic Adenocarcinoma Advanced or Metastatic; Lung Adenocarcinoma Metastatic; Cholangiocarcinoma Advanced; Cholangiocarcinoma Non-resectable; Mesothelin-expressing Advanced Cancers; Mesothelin-positive Advanced Malignant Solid Tumors; Colorectal Cancer
Interventions: Drug: CT-95
Sponsors: Context Therapeutics Inc.
Recruiting
Thu, 10 Jul 2025 00:00:00 EDT
Conditions: Mesothelioma; Malignant Mesothelioma (MM); Early-stage Mesothelioma; Subclinical Mesothelioma; BRCA1-Associated Protein-1 (BAP1) Mutations; Early-stage BAP1-associated Malignancies
Interventions: Drug: alrizomadlin
Sponsors: National Cancer Institute (NCI)
Not yet recruiting
Tue, 8 Jul 2025 00:00:00 EDT
Conditions: Unresectable Pleural Mesothelioma
Interventions: Drug: Volrustomig; Drug: Pemetrexed; Drug: Carboplatin; Drug: Cisplatin; Drug: Nivolumab; Drug: Ipilimumab
Sponsors: AstraZeneca
Recruiting
Thu, 10 Jul 2025 00:00:00 EDT
Conditions: High Grade Epithelial Ovarian Cancer; High Grade Serous Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Cancer; Endometrial Cancer; Non-small Cell Lung Cancer; Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC); Mesothelioma; Breast Adenocarcinoma; Triple Negative Breast Cancer; Hormone Receptor-positive/Her2 Negative Breast Cancer; Platinum-resistant Ovarian Cancer (PROC); Platinum Sensitive Ovarian Cancer (PSOC); Primary Refractory Ovarian Cancer; Uterine Cancer
Interventions: Drug: Rina-S; Drug: Carboplatin; Drug: Bevacizumab; Drug: Pembrolizumab
Sponsors: Genmab
Recruiting
Tue, 8 Jul 2025 00:00:00 EDT
Conditions: Cutaneous Melanoma; Non-small Cell Lung Cancer; Colorectal Neoplasms; Pancreatic Neoplasms; Mesothelioma
Interventions: Drug: PF-08046049
Sponsors: Seagen, a wholly owned subsidiary of Pfizer
Active, not recruiting
Thu, 10 Jul 2025 00:00:00 EDT
Conditions: Cervical Cancer; Colorectal Cancer; Esophageal Cancer; Gastric Cancer; Glioblastoma Multiforme; Cholangiocarcinoma; Hepatocellular Carcinoma; Head and Neck Squamous Cell Carcinoma; Nasopharyngeal Carcinoma; Non Small Cell Lung Cancer; Small Cell Lung Cancer; Epithelial Ovarian Cancer; Pancreatic Ductal Adenocarcinoma; Soft Tissue Sarcoma; Gastric Adenocarcinoma; Malignant Mesothelioma (MM); Von Hippel Lindau; Bladder Cancer; Bladder Urothelial Carcinoma
Interventions: Diagnostic Test: 89Zr-girentuximab for PET/CT imaging of CAIX positive tumors
Sponsors: Telix Pharmaceuticals (Innovations) Pty Ltd
Terminated
Wed, 9 Jul 2025 00:00:00 EDT
Conditions: Advanced Solid Tumor; Unresectable Solid Tumor; Clear Cell Renal Cell Carcinoma; Triple Negative Breast Cancer; Non-Small Cell Lung Cancer Squamous; Non-Small Cell Lung Cancer Non-squamous; Colorectal Cancer (MSI-H); Gastric Cancer; Cervical Cancer; Basal Cell Carcinoma; Bladder Cancer; Merkel Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; Cutaneous Squamous Cell Carcinoma; Pleural Mesothelioma; Esophageal Cancer; Endometrial Carcinoma; Solid Tumor; Solid Tumor, Adult; MSI-H Solid Malignant Tumor; Cancer With A High Tumor Mutational Burden; Epithelial Ovarian Carcinoma; Primary Peritoneal Cancer; Gastroesophageal Junction (GEJ) Cancer; Acral Melanoma; Mucosal Melanoma; Cutaneous Melanoma; DMMR Solid Malignant Tumor; Fallopian Tube Cancer; Ovarian Cancer; MSI-H Cancer; DMMR Cancer; Pancreas Adenocarcinoma (MSI-H); Skin Cancer; Viral Cancer; Cervical Cancers; Endometrial Cancer
Interventions: Drug: MDNA11; Drug: Pembrolizumab (KEYTRUDAź)
Sponsors: Medicenna Therapeutics, Inc.; Merck Sharp & Dohme LLC
Recruiting
Fri, 27 Jun 2025 00:00:00 EDT
Conditions: Peritoneal Malignant Mesothelioma
Interventions: Biological: Atezolizumab; Biological: Bevacizumab; Procedure: Biospecimen Collection; Drug: Carboplatin; Procedure: Computed Tomography; Procedure: Cytoreductive Surgery; Drug: Hyperthermic Intraperitoneal Chemotherapy; Drug: Pemetrexed; Procedure: Positron Emission Tomography
Sponsors: National Cancer Institute (NCI)
Recruiting
Menu